18 May 2026
Merck: sac‑TMT meets OS and PFS endpoints in Phase 3 TroFuse‑005 for advanced/recurrent endometrial cancer
TroFuse‑005 (776 pts) showed significant OS and PFS improvement vs chemotherapy in advanced/recurrent endometrial cancer after platinum and anti‑PD‑1/PD‑L1 therapy; ORR met; safety consistent.
